PLX-4720
≥99%
- Product Code: 77744
CAS:
918505-84-7
| Molecular Weight: | 413.83 g./mol | Molecular Formula: | C₁₇H₁₄ClF₂N₃O₃S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
PLX-4720 is primarily used in research settings to study its effects on cancer cells, particularly those with the BRAF V600E mutation. This mutation is commonly found in melanoma and other cancers. The compound acts as a selective inhibitor of the mutated BRAF protein, which plays a critical role in cell growth and proliferation. By blocking this protein, PLX-4720 helps to halt the uncontrolled growth of cancer cells. It serves as a valuable tool in preclinical studies to understand the mechanisms of BRAF inhibition and to evaluate potential therapeutic strategies for BRAF-mutated cancers. Additionally, it aids in the development of targeted therapies and combination treatments to improve outcomes for patients with these specific genetic alterations.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to Off-white to Yellow to Brown Solid |
| PURITY | 98.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿4,200.00 |
+
-
|
| 0.050 | 10-20 days | ฿6,300.00 |
+
-
|
| 0.250 | 10-20 days | ฿9,450.00 |
+
-
|
PLX-4720
PLX-4720 is primarily used in research settings to study its effects on cancer cells, particularly those with the BRAF V600E mutation. This mutation is commonly found in melanoma and other cancers. The compound acts as a selective inhibitor of the mutated BRAF protein, which plays a critical role in cell growth and proliferation. By blocking this protein, PLX-4720 helps to halt the uncontrolled growth of cancer cells. It serves as a valuable tool in preclinical studies to understand the mechanisms of BRAF inhibition and to evaluate potential therapeutic strategies for BRAF-mutated cancers. Additionally, it aids in the development of targeted therapies and combination treatments to improve outcomes for patients with these specific genetic alterations.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :